ERAS

Erasca Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$6.39B
P/E Ratio
EPS
$-0.95
Beta
0.65
52W High
$24.28
52W Low
$1.33
50-Day MA
$17.17
200-Day MA
$11.70
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Erasca Inc

Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers, aiming to meet significant unmet needs in oncology. Utilizing its proprietary drug discovery platform that merges advanced genomics with precision medicine, the company is committed to creating treatments that directly target the mutations responsible for cancer progression. Erasca boasts a strong pipeline of clinical-stage candidates designed to inhibit crucial tumor growth pathways, reinforcing its position as a leader in improving therapeutic standards and patient outcomes in cancer care. Strategic partnerships within the oncology research community bolster Erasca's reputation as a vital innovator in the biopharmaceutical landscape.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)0
Gross Profit (TTM)0
EBITDA$-147.74M
Operating Margin0.00%
Return on Equity-78.20%
Return on Assets-21.40%
Revenue/Share (TTM)$0.00
Book Value$1.16
Price-to-Book17.77
Price-to-Sales (TTM)
EV/Revenue-
EV/EBITDA-1.57
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$349.76M
Float$242.90M
% Insiders9.48%
% Institutions84.97%

Historical Volatility

HV 10-Day
35.13%
HV 20-Day
39.37%
HV 30-Day
61.40%
HV 60-Day
72.02%
HV Rank

Volatility is currently contracting

Analyst Ratings

Consensus ($23.30 target)
2
Strong Buy
6
Buy
2
Hold

Latest News

ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

New York, New York--(Newsfile Corp. - August 18, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). The investigation seeks to determine whether the Company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.

Newsfile Corp8/18/2026Neutral
ERASCA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action - ERAS

New York, New York--(Newsfile Corp. - August 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline. SO WHAT: If you purchased Erasca common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp8/10/2026Neutral
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline

SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights firm, is actively investigating claims in a class action alleging securities law violations at Erasca, Inc. (NASDAQ: ERAS). The litigation alleges Erasca and its senior executives misled investors by providing a false narrative regarding the competitive advantage, safety profile, and intellectual property (IP) moat surrounding its lead oncology candidate, ERAS-0015.

PRNewsWire8/10/2026Neutral
Erasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES, Aug. 10, 2026 /PRNewswire/ -- Schall Brown & Schwartz LLP, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Erasca, Inc. ("Erasca" or "the Company") (NASDAQ: ERAS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. If you purchased Erasca, Inc. securities you may be entitled to compensation without payment of any out-of-pocket fees or costs.

PRNewsWire8/10/2026Neutral
Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS

LOS ANGELES, Aug. 10, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Erasca, Inc. ("Erasca" or "the Company") (NASDAQ: ERAS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ERAS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

PRNewsWire8/10/2026Neutral
ERAS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Erasca To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Erasca between January 14, 2025 and April 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - August 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Newsfile Corp8/9/2026Neutral
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline

SAN FRANCISCO, Aug. 9, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights firm, is actively investigating claims in a class action alleging securities law violations at Erasca, Inc. (NASDAQ: ERAS). The litigation alleges Erasca and its senior executives misled investors by providing a false narrative regarding the competitive advantage, safety profile, and intellectual property (IP) moat surrounding its lead oncology candidate, ERAS-0015.

PRNewsWire8/9/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ERAS and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 8/18/2026